From L to R: Raghu Kalluri, Padmanee Sharma and Jim Allison (Allison Institute)
March 24, 2022 04:33 PM EDTUpdated March 26, 04:45 AM
R&D

Jim Al­li­son launch­es new in­sti­tute aimed at speed­ing drug de­vel­op­ment and rais­ing 'sur­vival curve for all can­cer­s'

Kyle LaHucik

Senior Reporter

Jim Al­li­son’s name is linked to a 2018 No­bel Prize, the im­mune sys­tem-ac­ti­vat­ing can­cer med Yer­voy and a host of ac­co­lades across his mul­ti …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times